JP2010525079A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525079A5
JP2010525079A5 JP2010506521A JP2010506521A JP2010525079A5 JP 2010525079 A5 JP2010525079 A5 JP 2010525079A5 JP 2010506521 A JP2010506521 A JP 2010506521A JP 2010506521 A JP2010506521 A JP 2010506521A JP 2010525079 A5 JP2010525079 A5 JP 2010525079A5
Authority
JP
Japan
Prior art keywords
dihydroxyvitamin
composition
patient
serum
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010506521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525079A (ja
JP5647516B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/061586 external-priority patent/WO2008134518A2/en
Publication of JP2010525079A publication Critical patent/JP2010525079A/ja
Publication of JP2010525079A5 publication Critical patent/JP2010525079A5/ja
Application granted granted Critical
Publication of JP5647516B2 publication Critical patent/JP5647516B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010506521A 2007-04-25 2008-04-25 ビタミンd療法のための方法および化合物 Expired - Fee Related JP5647516B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91384807P 2007-04-25 2007-04-25
US60/913,848 2007-04-25
PCT/US2008/061586 WO2008134518A2 (en) 2007-04-25 2008-04-25 Methods and compounds for vitamin d therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014186879A Division JP5952363B2 (ja) 2007-04-25 2014-09-12 ビタミンd療法のための方法および化合物

Publications (3)

Publication Number Publication Date
JP2010525079A JP2010525079A (ja) 2010-07-22
JP2010525079A5 true JP2010525079A5 (enExample) 2011-07-21
JP5647516B2 JP5647516B2 (ja) 2014-12-24

Family

ID=39926297

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010506521A Expired - Fee Related JP5647516B2 (ja) 2007-04-25 2008-04-25 ビタミンd療法のための方法および化合物
JP2014186879A Expired - Fee Related JP5952363B2 (ja) 2007-04-25 2014-09-12 ビタミンd療法のための方法および化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014186879A Expired - Fee Related JP5952363B2 (ja) 2007-04-25 2014-09-12 ビタミンd療法のための方法および化合物

Country Status (5)

Country Link
US (3) US8592401B2 (enExample)
EP (1) EP2148685A4 (enExample)
JP (2) JP5647516B2 (enExample)
CA (1) CA2684778C (enExample)
WO (1) WO2008134518A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882048C (en) 2006-02-03 2020-03-24 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
CA2684778C (en) * 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
WO2009111873A1 (en) * 2008-03-12 2009-09-17 Cytochroma, Inc. Stabilized 1,25-dihydroxyvitamin d2 and method of making same
PT2321273E (pt) * 2008-07-24 2014-12-29 Wisconsin Alumni Res Found Administração semanal de 25-hidroxi-vitamina d3 para manter concentração sanguínea elevada numa farmacocinética de estado estacionário
WO2010045558A1 (en) * 2008-10-17 2010-04-22 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
BRPI1005827A2 (pt) * 2009-02-23 2016-03-08 Univ Groningen composição farmacêutica e método para tratar um indivíduo sofrendo de uma doença causada por uma bactéria
CN103037902A (zh) 2010-03-29 2013-04-10 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
SG10201911274TA (en) * 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
EP4596045A3 (en) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Methods of vitamin d treatment
CN109219442A (zh) 2016-04-04 2019-01-15 Omeza有限公司 鱼油局部组合物
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565924A (en) * 1968-07-01 1971-02-23 Wisconsin Alumni Res Found 25-hydroxycholfcalciferol
US3880894A (en) * 1974-05-24 1975-04-29 Wisconsin Alumni Res Found 1,25-Dihydroxyergocalciferol
US4004003A (en) * 1974-08-28 1977-01-18 The Upjohn Company 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンd↓3類組成物
US4508651A (en) * 1983-03-21 1985-04-02 Hoffmann-La Roche Inc. Synthesis of 1α,25-dihydroxyergocalciferol
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4668517A (en) * 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
DE3676235D1 (de) * 1985-06-04 1991-01-31 Teijin Ltd Arzneizubereitung mit verzoegerter wirkstoffabgabe.
JPS61293911A (ja) 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5869473A (en) * 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP2845342B2 (ja) 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンd▲下3▼誘導体含有固形製剤組成物
JP2893140B2 (ja) 1990-11-30 1999-05-17 エスエス製薬株式会社 安定なビタミンd製剤
DK0508756T3 (da) * 1991-04-09 1997-03-24 Takeda Chemical Industries Ltd Stabiliseret vitamin D-præparat
US5693615A (en) * 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
AU4645893A (en) * 1992-06-22 1994-01-24 Lunar Corporation Oral 1alpha-hydroxyprevitamin D
US5354743A (en) * 1992-09-15 1994-10-11 Thys Jacobs Susan Method for the treatment of premenstrual syndrome with vitamin D
JPH07242550A (ja) 1994-03-02 1995-09-19 Teijin Ltd 二次性副甲状腺機能亢進症治療剤
IL110117A0 (en) 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
JPH0892098A (ja) 1994-09-27 1996-04-09 Teijin Ltd 肺結核治療剤
US6376479B1 (en) * 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
AU717238B2 (en) 1995-09-21 2000-03-23 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
DE19549243A1 (de) 1995-12-21 1997-06-26 Schering Ag Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga
EP0949927B1 (en) * 1996-08-26 2002-10-16 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
US6190591B1 (en) * 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
JPH10158171A (ja) 1996-12-02 1998-06-16 Kita:Kk ビタミンd化合物を配合した眼内投与剤
WO1999011272A1 (en) 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
ES2326502T3 (es) 1998-10-09 2009-10-13 General Mills, Inc. Encapsulacion de componentes liquidos sensibles en una matriz para obtener particulas discretas de larga conservacion.
AU765909C (en) * 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6432936B1 (en) * 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000059513A1 (en) * 1999-04-01 2000-10-12 Johns Hopkins University NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1α, 25-DIHYDROXY VITAMIN D¿3?
AU5139600A (en) * 1999-05-27 2000-12-18 Drugtech Corporation Nutritional formulations
US6274169B1 (en) * 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) * 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
IL153378A0 (en) * 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
PT1436257E (pt) * 2001-10-12 2007-05-31 Cytochroma Inc Análogos oxima de calcemia baixa de 1-alfa, 25-di-hidroxivitamina d3
US7056655B2 (en) 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
MXPA04005260A (es) 2001-12-03 2005-03-23 Novacea Inc Composiciones farmaceuticas que comprenden compuestos activos de vitamina d.
WO2003106411A1 (en) * 2002-06-13 2003-12-24 Johns Hopkins University 24-sulfoximine vitamin d3 compounds
WO2004028515A1 (en) 2002-09-26 2004-04-08 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
JP2004175750A (ja) 2002-11-28 2004-06-24 Kose Corp 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤
JP2006514695A (ja) 2002-12-16 2006-05-11 テバ ファーマシューティカル インダストリーズ リミティド ビタミンd誘導体の前用量投与によってアレンドロネート又は他のビスフォスフォネートの全体利用効率を高める方法
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050124591A1 (en) * 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
US20060171983A1 (en) * 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
EP1765385A4 (en) 2004-06-16 2008-08-27 Smart Drug Systems Inc IMPORTS COMPOSITION WITH DELAYED RELEASE
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US20070122477A1 (en) 2005-10-12 2007-05-31 Cytochroma, Inc. Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
CA2882048C (en) * 2006-02-03 2020-03-24 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
ES2401205T3 (es) * 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
CA2683514C (en) 2007-04-25 2019-07-09 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CA2684778C (en) * 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
PT2321273E (pt) 2008-07-24 2014-12-29 Wisconsin Alumni Res Found Administração semanal de 25-hidroxi-vitamina d3 para manter concentração sanguínea elevada numa farmacocinética de estado estacionário

Similar Documents

Publication Publication Date Title
JP2017002086A5 (enExample)
KR101495578B1 (ko) 비타민 d 부족 및 결핍의 치료 방법
Petkovich et al. Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation
Goodman Recent developments in the management of secondary hyperparathyroidism
JP2017075183A5 (enExample)
JP5563296B2 (ja) 二次性副甲状腺機能亢進症の治療及び予防方法
JP2010525078A5 (enExample)
FI3225243T3 (fi) Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä
CN112423789A (zh) 用于治疗抑郁症的艾司氯胺酮
US10357501B2 (en) Treating conditions associated with increased eotaxin with 25-hydroxyvitamin D3
JP2009541348A5 (enExample)
Souberbielle et al. Vitamin D supplementation in France in patients with or at risk for osteoporosis: recent data and new practices
CN101801389A (zh) 用于提供活力、压力纾缓和情绪提升有益效果的包括施用包含胆钙化醇和茶叶提取物的组合物的方法
JP2006519854A5 (enExample)
US20250144119A1 (en) Activating endogenous antimicrobials to treat sars-cov-2 infection
CN101304753B (zh) 镧化合物的制药用途
US11903952B2 (en) Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection
JP2025031720A5 (enExample)
US20230193219A1 (en) Superoxide dismutase compositions and methods
US20110250273A1 (en) Compositions of proton pump inhibitors, kits and methods of their use to treat diabetes
EP2289555A1 (en) Method of treating frailty
US20210177875A1 (en) Methods and compositions for treating childhood or teen obesity
TW201105333A (en) Agent for preventing non-traumatic vertebral fracture in severe osteoporosis patients which comprises eldecalcitol
US20230165928A1 (en) Compositions and methods comprising stable reduced glutathione
EP4326279A1 (en) Universal dosage regime of 25-hydroxy vitamin d3